A Phase 1 Dose-Escalation Study of Intravenous MST-997 Formulated in Polysorbate 80 Diluent Administered Weekly in Subjects With Advanced Malignant Solid Tumors
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the safety, tolerability and MTD (maximum tolerated dose) of MST-997.
Wyeth is now a wholly owned subsidiary of Pfizer
United States: Food and Drug Administration
|Austin, Texas 78705|